Defining metabolic syndrome and factors associated with metabolic syndrome in a poly-pharmaceutical population

References

• Kylin E. Studies of the hypertension hyperglycemia hyperuricemia syndrome. Zentralbl Innere Med. 1923;44:105–127.
   Google Scholar
• Parikh RM, Mohan V. Changing definitions of metabolic syndrome. Indian J Endocrinol Metab. 2012;16(1):7–12. DOI:10.4103/2230-8210.91175.
   PubMedGoogle Scholar
• Grundy SM, Cleeman JI, Daniels SR, et al.. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement [published corrections appear in Circulation. 2005;112: e297and Circulation. 2005;112:e298]. Circulation. 2005;112:2735–2752.
   PubMed Web of Science ®Google Scholar
• Alberti KG, Zimmet P, Shaw J, et al.. The metabolic syndrome: a new worldwide definition. Lancet. 2005;366:1059–1062.
   PubMed Web of Science ®Google Scholar
• Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000;355(9200):253–259.
   PubMed Web of Science ®Google Scholar
• Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial. Lancet. 2002;360(9326):7–22.
   PubMed Web of Science ®Google Scholar
• Institute For Public Health (IPH) 2015. National Health and Morbidity Survey 2015 (NHMS 2015). Vol I: Methodology and General Findings. Putrajaya (Malaysia): Ministry of Health; 2015.
   Google Scholar
• Khoo KL, Tan H, Khoo TH. Cardiovascular mortality in Peninsular Malaysia: 1950–1989. Med J Malaysia. 1991;46:7–20.
   PubMedGoogle Scholar
• Ministry of Health, Malaysia. Malaysian Statistics on Medicines; 2015 [cited 2016 Aug 17]. Available from: http://www.pharmacy.gov.my/v2/en/documents/malaysian-statistics-medicines.html
   Google Scholar
• WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment. 18th ed. Oslo: Norwegian Institute of Public Health; 2015. p. 275.
   Google Scholar
• International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome. International Diabetes Federation (IDF); 2006 [cited 2016 Aug 17]. Available from: https://www.idf.org/webdata/docs/MetS_def_update2006.pdf
   Google Scholar
• Van De Laar FA, Lucassen PLBJ, Akkermans RP, et al. Alpha- glucosidase inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2005;2:Art. No.: CD003639. DOI:10.1002/14651858.CD003639.pub2
   PubMed Web of Science ®Google Scholar
• Heran BS, Galm BP, Wright JM. Blood pressure lowering efficacy of alpha blockers for primary hypertension. Cochrane Database Syst Rev. 2012;Issue 8:Art. No.: CD004643. DOI:10.1002/14651858.CD004643.pub3
   Web of Science ®Google Scholar
• Chen JMH, Heran BS, Wright JM. Blood pressure lowering efficacy of diuretics as second-line therapy for primary hypertension. Cochrane Database Syst Rev. 2009;Issue 4:Art. No.: CD007187. DOI:10.1002/14651858.CD007187.pub2
   Web of Science ®Google Scholar
• Musini VM, Rezapour P, Wright JM, et al. Blood pressure-lowering efficacy of loop diuretics for primary hypertension. Cochrane Database Syst Rev. 2015;Issue 5:Art. No.: CD003825. DOI:10.1002/14651858.CD003825.pub4
   PubMed Web of Science ®Google Scholar
• Wong GWK, Wright JM. Blood pressure lowering efficacy of nonselective beta-blockers for primary hypertension. Cochrane Database Syst Rev. 2014;Issue 2:Art. No.: CD007452. DOI:10.1002/14651858.CD007452.pub2
   Web of Science ®Google Scholar
• Heran BS, Wong MMY, Heran IK. Wright JM. Blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension. Cochrane Database Syst Rev. 2008;Issue 4:Art. No.: CD003823. DOI:10.1002/14651858.CD003823.pub2
   Web of Science ®Google Scholar
• Shepherd J, Blauw G, Murphy M, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623–1630.
   PubMed Web of Science ®Google Scholar
• Sever PS, Dahlöf B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149–1158.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Danielson E, Fonseca FA, et al.; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.
   PubMed Web of Science ®Google Scholar
• Cameron AC, Trivedi PK. Macroeconometrics: methods and applications. New York (NY): Cambridge University Press; 2005. Chapter 20, Models of count data; p. 665–691.
   Google Scholar
• Wan Nazaimoon WM, Aziz SI, Amir Sharifuddin MK, et al. Prevalence of metabolic syndrome and its risk factors in adult Malaysians: results of a nationwide survey. Diabetes Res Clin Pract. 2013;96(1):91–97.
   Web of Science ®Google Scholar
• Tan C-E, Ma S, Wai D, et al. Can we apply the national cholesterol education program adult treatment panel definition of the metabolic syndrome to Asians? Diabetes Care. 2004;27:1182–1186.
   PubMed Web of Science ®Google Scholar
• Hor JY. Prescription drug use among elderly admitted to medical wards in a Malaysian government hospital. Med J Malaysia. 2008;65(3):125–130.
   Google Scholar
• Woo J, Ho SC, Yuen YK, et al. Drug use in an elderly Chinese population: prevalence and associated factors. Gerontology. 1995;41:98–108.
   PubMed Web of Science ®Google Scholar
• Hanlon JT, Fillenbaum GG, Burchett B, et al. patterns among Black and Nonblack community-dwelling elderly. Ann Pharmacother. 1992;26:679–685.
   PubMed Web of Science ®Google Scholar
• Jörgensen TM, Isacson DGL, Thorslund M. Prescription drug use among ambulatory elderly in a Swedish municipality. Ann Pharmacother. 1993;27:1120–1125.
   PubMed Web of Science ®Google Scholar
• Simons LA, Tett S, Simons J, et al. Multiple medication use in the elderly: use of prescription and non-prescription drugs in an Australian community setting. Med J Aust. 1992;157:242–246.
   PubMed Web of Science ®Google Scholar
• Cahir C, Fahey T, Teeling M, et al. Potentially inappropriate prescribing and cost outcomes for older people: a national population study. Br J Clin Pharmacol. 2010 May;69(5):543–552.
   PubMed Web of Science ®Google Scholar
• Barros AJ, Hirakata VN. Alternatives for logistic regression in cross-sectional studies: an empirical comparison of models that directly estimate the prevalence ratio. BMC Med Res Methodol. 2003;3:21. DOI:10.1186/1471-2288-3-21
   PubMedGoogle Scholar
• Fekedulegn D, Andrew M, Violanti J, et al. Comparison of statistical approaches to evaluate factors associated with metabolic syndrome. J Hypertens. 2010;12:365–373.
   Web of Science ®Google Scholar